We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-3.47%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$119B
AUM Growth
-$5.47B
Cap. Flow
+$963M
Cap. Flow %
0.81%
Top 10 Hldgs %
23.93%
Holding
4,385
New
262
Increased
2,061
Reduced
1,644
Closed
273

Sector Composition

Rank Sector Weight
1 Technology 14.55%
2 Financials 8.81%
3 Healthcare 8.45%
4 Industrials 6.22%
5 Consumer Discretionary 6.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
JVA icon
3826
Coffee Holding Co
JVA
$19.9M
$92K ﹤0.01%
26,800
DBI icon
3827
CALL
Designer Brands
DBI
$321M
$91K ﹤0.01%
47,900
+8,900
+23% +$118K
PLAY icon
3828
CALL
Dave & Buster's
PLAY
$349M
$91K ﹤0.01%
25,300
+800
+3% +$32K
WT icon
3829
WisdomTree
WT
$3.33B
$91K ﹤0.01%
15,448
+1,375
+10% +$7.86K
NSLR
3830
Neostellar Capital Corp
NSLR
$282M
$90K ﹤0.01%
+10,486
New +$118K
SLHG
3831
DELISTED
Skylight Health Group Inc Common Shares
SLHG
$90K ﹤0.01%
+85,293
New +$86K
DNN icon
3832
Denison Mines
DNN
$3B
$89K ﹤0.01%
55,640
+11,000
+25% +$15.5K
EDIT icon
3833
CALL
Editas Medicine
EDIT
$453M
$89K ﹤0.01%
+34,100
New +$634K
EXEL icon
3834
CALL
Exelixis
EXEL
$12.7B
$88K ﹤0.01%
+29,200
New +$570K
MFA
3835
MFA Financial
MFA
$928M
$88K ﹤0.01%
5,453
-900
-14% -$15.6K
OXY icon
3836
PUT
Occidental Petroleum
OXY
$59B
$88K ﹤0.01%
+80,000
New +$3.54M
DHC
3837
Diversified Healthcare Trust
DHC
$1.98B
$87K ﹤0.01%
27,267
-737
-3% -$2.25K
NEXI
3838
DELISTED
NexImmune, Inc. Common Stock
NEXI
$87K ﹤0.01%
+825
New +$60.6K
NOG icon
3839
CALL
Northern Oil and Gas
NOG
$2.58B
$86K ﹤0.01%
57,900
-41,300
-42% -$1.01M
JEMD
3840
DELISTED
Nuveen Emerging Markets Debt 2022 Target Term Fund, Common Shares of Beneficial Interest, $0.01 par value per share
JEMD
$86K ﹤0.01%
12,337
-7,738
-39% -$56.2K
IMMR icon
3841
Immersion
IMMR
$248M
$84K ﹤0.01%
15,163
-1,644
-10% -$8.52K
NUVB icon
3842
Nuvation Bio
NUVB
$2.24B
$84K ﹤0.01%
16,060
+3,600
+29% +$20.2K
PRVB
3843
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$83K ﹤0.01%
11,400
-8,600
-43% -$51.4K
MPLX icon
3844
CALL
MPLX
MPLX
$60.1B
$82K ﹤0.01%
45,400
-100
-0.2% -$3.23K
CHS
3845
DELISTED
Chicos FAS, Inc.
CHS
$82K ﹤0.01%
17,033
-8,402
-33% -$39.3K
TTSH
3846
DELISTED
Tile Shop Holdings
TTSH
$81K ﹤0.01%
+12,294
New +$80.7K
OMQS
3847
DELISTED
OMNIQ Corp. Common Stock
OMQS
$81K ﹤0.01%
12,000
INTC icon
3848
CALL
Intel
INTC
$493B
$80K ﹤0.01%
164,700
+34,900
+27% +$1.73M
SEI
3849
CALL
Solaris Energy Infrastructure
SEI
$3.87B
$77K ﹤0.01%
+139,800
New +$1.27M
BLMN icon
3850
CALL
Bloomin' Brands
BLMN
$952M
$76K ﹤0.01%
66,800
+48,500
+265% +$1.05M

Similar funds

Raymond James & Associates's Q1 2022 Portfolio in Review

As of Q1 2022, Raymond James & Associates held 4,385 positions worth $119B, down 4.4% from $124B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Raymond James & Associates's Q1 2022 filing shows 262 new, 2,061 increased, 1,644 reduced and 273 closed positions. Its largest new stake was Shell: 688,334 shares worth $37.8M. The largest sale was iShares Ultra Short Duration Bond Active ETF, an estimated $172M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 15% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q1 2022 buy was Shell: 688,334 shares worth $37.8M.
  • Raymond James & Associates added most to Broadcom in Q1 2022, an estimated $236M increase.
  • Raymond James & Associates's biggest Q1 2022 reduction was iShares Ultra Short Duration Bond Active ETF, cutting an estimated $172M.
  • Raymond James & Associates fully exited IHS Markit Ltd. Common Shares in Q1 2022, selling an estimated $154M.
  • Raymond James & Associates's ten largest holdings make up 24% of its $119B portfolio in Q1 2022.
  • Raymond James & Associates opened 262 new positions and closed 273 in Q1 2022.
  • Raymond James & Associates's portfolio value fell 4.4% quarter-over-quarter to $119B.

Based on Raymond James & Associates's 13F filing for Q1 2022, filed 11 May 2022.